m-CPP, a 5-HT2C Receptor Agonist That Modifies the Perfusion Pressure of the Hindquarter Vascular Bed of Anesthetized Rat

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Pharmacology

• Publication date

  2005-01-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1159/000081078PMID 15452415
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 5‐Hydroxytryptamine‐induced vasodilator responses in the hindquarters of the anaesthetized rat, involve β2‐adrenoceptors

  2003cited by this paper
• Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia

  2003cited by this paper
• Vasodilator and vasoconstrictor responses induced by 5-hydroxytryptamine in the in situ blood autoperfused hindquarters of the anaesthetized rat

  2002cited by this paper
• Unravelling the pharmacological profile of the canine external carotid vasodilator '5-HT1-like' receptors: coexistence of sympatho-inhibitory 5-HT1B and postjunctional 5-HT7 receptors

  2000cited by this paper
• SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.

  1999cited by this paper
• Crucial role of the 5-HT2C receptor, but not of the 5-HT2A receptor, in the down regulation of stimulated dopamine release produced by pressure exposure in freely moving rats.

  1998cited by this paper
• Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens.

  1998cited by this paper
• Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

  1998cited by this paper
• Renal vasoconstrictor response to 5-hydroxytryptamine in the in situ autoperfused rat kidney: involvement of angiotensin II and the 5-HT2 receptor activation.

  1997cited by this paper
• SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors

  1997cited by this paper
• 5‐Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats

  1996cited by this paper
• Paraventricular nucleus controls 5-HT2C receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses.

  1995cited by this paper
• International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

  1994cited by this paper
• Effect of selective serotonin agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells.

  1993cited by this paper
• Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists.

  1992cited by this paper
• Effect of 5-HT1C and 5-HT2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations.

  1992cited by this paper
• Analogues of the 5-HT1A serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine with reduced alpha 1-adrenergic affinity.

  1991cited by this paper
• m-Chlorophenylpiperazine as a probe of serotonin function.

  1991cited by this paper
• Beta-endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action.

  1990cited by this paper
• Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists

  1990cited by this paper
• Effects of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami.

  1989cited by this paper
• Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.

  1989cited by this paper
• Molecular pharmacology and biology of 5-HT1C receptors.

  1988cited by this paper
• Pharmacological profile of ritanserin: A very specific central serotonin S2‐antagonist

  1988cited by this paper
• The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551).

  1983cited by this paper
• The Pharmacology of a β2‐Selective Adrenoceptor Antagonist (ICI 118,551)

  1983cited by this paper
• Comparison of the pharmacological characteristics of 5 HT1 and 5 HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release

  1982cited by this paper
• Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats.

  1981cited by this paper
• A method for the study of peripheral vascular responses in the rat

  1963cited by this paper

• Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

  2020cites this paper
• 5-HT2 receptor blockade exhibits 5-HT vasodilator effects via nitric oxide, prostacyclin and ATP-sensitive potassium channels in rat renal vasculature.

  2016cites this paper
• Participation of cyclooxygenase pathway in the vasoconstriction induced by 5-HT in the in situ autoperfused kidney of long-term diabetic rats.

  2011cites this paper
• Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat.

  2008cites this paper